Text Size

Attenuated Inflammatory Response in Laparoscopic Colon Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dag T Førland, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01419431
First received: July 18, 2011
Last updated: December 15, 2011
Last verified: December 2011
History of Changes
  Purpose

Pro-inflammatory responses following laparoscopic surgery.


Condition Intervention
Regulation of Inflammatory Response
 Procedure: Laparoscopic resection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Increased SOCS 3 mRNA in Monocytes From Patients Subjected to Laparoscopic Colon Surgery

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Inflammatory values for laparoscopic resection for colon cancer. [ Time Frame: 3 days ] [ Designated as safety issue: No ]
    Corresponding values of SOCS3 mRNA copared to inflammatory cytokines in patients with laparoscopic resection for colon cancer.


Estimated Enrollment: 20
Study Start Date: January 2007
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Colon cancer patients
Laparoscopic resection
 Procedure: Laparoscopic resection
Inflammatory response in laparoscopic surgery
Other Name: Colon cancer

Detailed Description:

Blood samples from 20 patient with colon cancer collected before and in 3 days following laparoscopic surgery. Analyzed for inflammatory cytokines and corresponding SOCS3 mRNA.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Colon cancer stage I-III

Criteria

Inclusion Criteria:Colon cancer stage I-III -

Exclusion Criteria:Colon cancer stage IV

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01419431

Locations
Norway
Oslo University Hospital
Oslo, Norway, 0407
Sponsors and Collaborators
Oslo University Hospital
Investigators
Principal Investigator: Dag T. Førland, MD OUS
  More Information

No publications provided

Responsible Party: Dag T Førland, MD, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01419431     History of Changes
Other Study ID Numbers: SOCS3 mRNA, SOCS-3-202008
Study First Received: July 18, 2011
Last Updated: December 15, 2011
Health Authority: Norway: Regional Ethics Commitee

Keywords provided by Oslo University Hospital:
Colon cancer

ClinicalTrials.gov processed this record on May 23, 2013